CPI 893
Alternative Names: CPI-893Latest Information Update: 28 Jan 2023
Price :
$50 *
At a glance
- Originator Corvus Pharmaceuticals
- Developer Corvus Pharmaceuticals; Mayo Clinic; University of Michigan
- Class Antineoplastics; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported T-cell lymphoma
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in T-cell-lymphoma in USA
- 01 Dec 2018 Preclinical trials in T-cell lymphoma in USA (unspecified route) prior to December 2018
- 01 Dec 2018 Pharmacodynamics data from a preclinical trial in T-cell lumphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)